Search
Searching Content indexed under Healthcare by Kristin Wall ordered by Published Date Descending.
Links to Result pages
 
1  
 
Title
Country
Organisation
Author
Date
2
Budget 2019: Federal Government Announces Intention To Implement Recommendations On National Pharmacare
Yesterday, the federal government announced funding to implement this recommendation.
Canada
22 Mar 2019
3
Health Canada Consulting On The Contents Of The Generic Submissions Under Review List
On January 7, 2019, Health Canada opened a consultation on whether to include the names of sponsor companies on the generic submissions under review list (GSUR) ...
Canada
31 Jan 2019
4
Top Headlines Of 2018
Last year ushered in a number of changes to the Canadian pharmaceutical and life sciences sector.
Canada
18 Jan 2019
5
Abbreviated New Drug Submissions Will Be Posted On The Submissions Under Review List And Other Pre-Market Transparency Initiatives
Health Canada recently published a notice outlining its phase III pre-market transparency initiatives for prescription drugs.
Canada
16 Oct 2018
6
Health Canada Releases Updated Guidance On Amended PM(NOC) Regulations
•The scope and application of section 5 of Regulations, including providing clarification for the types of submissions that will be captured by the provision when a second person applies for an NOC.
Canada
15 Aug 2018
7
Pan-Canadian Pharmaceutical Alliance (pCPA) Releases Draft Brand Process Guidelines
On June 13, 2018, the pan-Canadian Pharmaceutical Alliance (pCPA) released its draft Brand Process Guidelines (Guidelines) for stakeholder feedback.
Canada
21 Jun 2018
8
Health Canada Issues Notice Of Impact Of FCA Case On PM(NOC) Guidance Document
Health Canada recently published a notice regarding the Guidance Document: Patented Medicines (Notice of Compliance) Regulations.
Canada
9 Nov 2016
9
Pharma In Brief - "Dear Health Care Professional Letter" No Longer Required For Notice Of Compliance With Conditions (NOC/C)
Health Canada no longer requires manufacturers to prepare a "Dear Health Care Professional Letter" for drugs that have been issued a Notice of Compliance with conditions (NOC/c).
Canada
27 Oct 2016
10
Minister's Decision To Issue NOC Without Notice To First Person For Cross-Referenced Drug Submission Held Reasonable By The FCA
This appeal relates to two generic drug submissions for two different products: exemestane and infliximab. Both submissions cross-referenced the submission of another generic company that had received a Notice of Compliance.
Canada
19 Oct 2016
11
Update: SCC Denies Leave To Appeal – Pharmacy Customer Incentive/Loyalty Programs For Drugs And Pharmacy Services Remain Prohibited In BC
The College of Pharmacists of British Columbia (CPBC) is the regulatory body responsible for licensing and registering pharmacists, pharmacies and pharmacy technicians in British Columbia.
Canada
11 Jul 2016
12
Pharma In Brief - Update On Regulatory Pharmaceutical Naming Issues
Over the past year, there were a number of notable developments in matters relating to branding and naming of pharmaceutical products in Canada.
Canada
17 Mar 2014
13
Pharma In Brief - Supreme Court Of Canada Grants Apotex Leave To Appeal (Again) In Regard To The PLAVIX® Patent
On January 30, 2014, the Supreme Court of Canada ("SCC") granted Apotex Inc., et al. ("Apotex") leave to appeal the July 24, 2013 Federal Court of Appeal order declaring Canadian Patent No. 1,336,777 ("‘777 Patent") to be valid and infringed ("FCA Decision").
Canada
4 Feb 2014
14
Pharma In Brief - Canada: Merck Awarded Substantial Damages For Infringement Of Lovastatin Patent
The Federal Court held that Merck and Co., Inc. ("Merck US") and Merck Canada Inc. ("Merck Canada") (collectively "Merck") are entitled to $119,054,327 in damages plus pre and post judgment interest arising from Apotex Inc.’s ("Apotex") infringement of Canadian Patent No 1,161,380 (the "‘380 Patent") with respect to the anti-cholesterol drug MEVACOR (lovastatin).
Canada
1 Aug 2013
15
European Union - Canada Debate IP Rights For Pharmaceuticals
Norton Rose Group’s head of pharmaceuticals and life sciences, Patrick Kierans (based in Toronto), together with partners Richard A. Wagner (Ottawa) and Mélanie Thill-Tayara (Paris), assess the recent response by Canadian generic manufacturers to proposed reform of intellectual property law in Canada.
Canada
13 Jul 2011
Links to Result pages
 
1